SQLE as a potential diagnostic and prognostic biomarker for LIHC: a multi-cohort and spatial study.
A metabolic enzyme emerges as both a marker and potential drug target in liver cancer, linking cancer growth to cholesterol-making processes.
A multi-cohort and spatial transcriptomics study identifies SQLE (squalene epoxidase) as a diagnostic and prognostic biomarker in hepatocellular carcinoma, validated across multiple independent cohorts. SQLE is part of cholesterol synthesis and represents a metabolic vulnerability potentially targetable in liver cancer.
What the study was
- Study design
- Multi-cohort retrospective biomarker study with spatial transcriptomics
- Population
- Hepatocellular carcinoma (LIHC) patients; multi-cohort analysis
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- NPJ precision oncology
Why it surfaced
Multi-cohort validated biomarker in HCC; spatial transcriptomics data is a strength. Sample size unknown from abstract.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.